COMMUNIQUÉS West-GlobeNewswire
-
Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles
21/07/2026 -
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
21/07/2026 -
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
21/07/2026 -
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
21/07/2026 -
Applied Biologics Initiates Multi-Center Real-World Outcomes Study of XWRAP® Across Chronic Wound Types
21/07/2026 -
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
21/07/2026 -
Kraig Biocraft Laboratories CEO Kim Thompson Featured in Just Style, a Leading Global Apparel Industry Trade Publication
21/07/2026 -
Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange
21/07/2026 -
Allogenetics Appoints Dr. Jeroen Rovers as Chief Medical Officer
21/07/2026 -
Transactions in connection with share buy-back program
21/07/2026 -
Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting
21/07/2026 -
OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA
21/07/2026 -
Carbios reaches milestone of 100 batches at its Industrial demonstration plant and expands its licensing offering to the textile market
21/07/2026 -
Carbios franchit le cap des 100 batchs produits au sein de son démonstrateur industriel et étend son offre de licences au marché textile
21/07/2026 -
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
21/07/2026 -
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
21/07/2026 -
UPDATE: Conceivable Life Sciences Strengthens Senior Leadership Team to Support IVI RMA Partnership and U.S. Launch
21/07/2026 -
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
20/07/2026 -
Park Dental Partners Announces Dates for Second Quarter 2026 Earnings Release and Conference Call
20/07/2026
Pages